Drug
Nintedanib (OFEV®)
Status:
To Patients
Condition:
Systemic Sclerosis ILD
Intervention Type:
Oral Drug
Funder Type:
Industry
Drug Details
Nintedanib (OFEV®) is an anti-fibrotic drug that is approved to treat Systemic Sclerosis ILD in the United States. In clinical trials, nintedanib has been shown to slow the progression of lung function decline in this patient population.